Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study

• DOI: 10.1161/circulationaha.116.026859
• Publication Date: 2017-05-09T00:50:24Z
• Authors: Joseph B. Lerman; Aditya A. Joshi; Abhishek Chaturvedi; Tsion M. Aberra; Amit K. Dey; Justin A. Rodante; Taufiq Salahuddin; Jonathan H. Chung; Anshuma Rana; Heather L. Teague; Jashin J. Wu; Martin P. Playford; Benjamin A. Lockshin; Marcus Y. Chen; Veit Sandfort; David A. Bluemke; Nehal N. Mehta
• Keywords: Subclinical infection; Hyperlipidemia

Background: Psoriasis, a chronic inflammatory disease associated with an accelerated risk of myocardial infarction, provides ideal human model to study atherogenesis in vivo. We hypothesized that the increased cardiovascular observed psoriasis would be partially attributable elevated subclinical coronary artery burden composed noncalcified plaques high-risk features. However, inadequate efforts have been made directly measure this vulnerable population. As such, we sought compare total plaque and (NCB) (HRP) prevalence between patients (n=105), hyperlipidemia eligible for statin therapy under National Cholesterol Education Program-Adult Treatment Panel III guidelines (n=100) who were ≈10 years older, healthy volunteers without (n=25). Methods: Patients underwent computed-tomography angiography NCB quantification HRP identification, defined as low attenuation (<30 hounsfield units), positive remodeling (>1.10), spotty calcification. A consecutive sample first 50 was scanned again 1 year after therapy. Results: Despite being younger at lower traditional than hyperlipidemia, had (mean±SD: 1.18±0.33 versus 1.11±0.32, P =0.02) similar ( =0.58). Furthermore, compared volunteers, (1.22±0.31 1.04±0.22, =0.001), (1.18±0.33 1.03±0.21, =0.004), beyond (odds ratio, 6.0; 95% confidence interval, 1.1–31.7; =0.03). Last, among followed year, improvement severity (β=0.45, 0.23–0.67; <0.001) (β=0.53, 0.32–0.74; factors. Conclusions: greater volunteers. In addition, equivalent older hyperlipidemia. modulation target organ inflammation (eg, skin) suggesting control remote sites may translate into reduced risk.